IMI's overall goal is to build a more collaborative ecosystem for pharmaceutical R&D in Europe and to speed up the development of more effective and safer medicines for patients.
To reach this objective, IMI creates unique, large-scale networks of innovation in pharmaceutical research. Joining forces in the IMI research and training projects, competing pharmaceutical companies collaborate with each other and with academia, regulatory agencies and patients' organisations in order to tackle the major challenges in drug development.
The main challenges are:
- Industrial: insufficient R&D investment
- Scientific: technological complexity
- At European level: research in Europe is fragmented and tends to be located elsewhere.
To address these challenges, IMI will harness the know-how and expertise available across Europe's biopharmaceutical sector, by pooling competencies and resources from the public and the private domain.
The research activities, supported by the IMI, will be open to all research actors, provided that they are performed within Europe.